<?xml version='1.0' encoding='utf-8'?>
<document id="23720017"><sentence text="Age related changes in fractional elimination pathways for drugs: assessing the impact of variable ontogeny on metabolic drug-drug interactions." /><sentence text="The magnitude of any metabolic drug-drug interactions (DDIs) depends on fractional importance of inhibited pathway which may not necessarily be the same in young children when compared to adults" /><sentence text=" The ontogeny pattern of cytochrome P450 (CYP) enzymes (CYPs 1A2, 2B6, 2C8, 2C9, 2C18/19, 2D6, 2E1, 3A4) and renal function were analyzed systematically" /><sentence text=" Bootstrap methodology was used to account for variability, and to define the age range over which statistical differences existed between each pair of specific pathways" /><sentence text=" A number of DDIs were simulated (Simcyp Pediatric v12) for virtual compounds to highlight effects of age on fractional elimination and consequent magnitude of DDI" /><sentence text=" For a theoretical drug metabolized 50% by each of CYP2D6 and CYP3A4 pathways at birth, co-administration of ketoconazole (3 mg/kg) resulted in a 1"><entity charOffset="109-121" id="DDI-PubMed.23720017.s6.e0" text="ketoconazole" /></sentence><sentence text="65-fold difference between inhibited versus uninhibited AUC compared to 2" /><sentence text="4-fold in 1 year olds and 3" /><sentence text="2-fold in adults" /><sentence text=" Conversely, neonates could be more sensitive to DDI than adults in certain scenarios" /><sentence text=" Thus, extrapolation from adult data may not be applicable across all pediatric age groups" /><sentence text=" The use of pediatric physiologically based pharmacokinetic (p-PBPK) models may offer an interim solution to uncovering potential periods of vulnerability to DDI where there are no existing clinical data derived from children" /><sentence text="" /></document>